Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101139802 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2875 (Electronic) Linking ISSN: 14752875 NLM ISO Abbreviation: Malar J Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2002-
    • الموضوع:
      Drug Resistance* ; Mutation, Missense*; Antimalarials/*pharmacology ; Folic Acid Antagonists/*pharmacology ; Malaria, Falciparum/*parasitology ; Plasmodium falciparum/*drug effects ; Plasmodium falciparum/*genetics; Adult ; Afghanistan/epidemiology ; Artemisinins/pharmacology ; Artemisinins/therapeutic use ; Artesunate ; Child ; Child, Preschool ; DNA, Protozoan/genetics ; Drug Combinations ; Folic Acid Antagonists/therapeutic use ; Humans ; Malaria, Falciparum/drug therapy ; Malaria, Falciparum/epidemiology ; Polymerase Chain Reaction ; Prevalence ; Protozoan Proteins/genetics ; Pyrimethamine/pharmacology ; Pyrimethamine/therapeutic use ; Sulfadoxine/pharmacology ; Sulfadoxine/therapeutic use
    • نبذة مختصرة :
      Background: Artesunate plus sulphadoxine-pyrimethamine (AS+SP) is now first-line treatment for Plasmodium falciparum infection in several south Asian countries, including Afghanistan. Molecular studies provide a sensitive means to investigate the current state of drug susceptibility to the SP component, and can also provide information on the likely efficacy of other potential forms of artemisinin-combination therapy.
      Methods: During the years 2007 to 2010, 120 blood spots from patients with P. falciparum malaria were obtained in four provinces of Afghanistan. PCR-based methods were used to detect drug-resistance mutations in dhfr, dhps, pfcrt and pfmdr1, as well as to determine copy number of pfmdr1.
      Results: The majority (95.5%) of infections had a double mutation in the dhfr gene (C59R, S108N); no mutations at dhfr positions 16, 51 or 164 were seen. Most isolates were wild type across the dhps gene, but five isolates from the provinces of Kunar and Nangarhar in eastern Afghanistan had the triple mutation A437G / K540E / A581G; all five cases were successfully treated with three receiving AS+SP and two receiving dihydroartemisinin-piperaquine. All isolates showed the pfcrt SVNMT chloroquine resistance haplotype. Five of 79 isolates had the pfmdr1 N86Y mutation, while 52 had pfmdr1 Y184F; positions 1034, 1042 and 1246 were wild type in all isolates. The pfmdr1 gene was not amplified in any sample.
      Conclusions: This study indicates that shortly after the adoption of AS+SP as first-line treatment in Afghanistan, most parasites had a double mutation haplotype in dhfr, and a small number of isolates from eastern Afghanistan harboured a triple mutation haplotype in dhps. The impact of these mutations on the efficacy of AS+SP remains to be assessed in significant numbers of patients, but these results are clearly concerning since they suggest a higher degree of SP resistance than previously detected. Further focused molecular and clinical studies in this region are urgently required.
    • References:
      Trans R Soc Trop Med Hyg. 1989 May-Jun;83(3):316. (PMID: 2694464)
      Antimicrob Agents Chemother. 2010 Sep;54(9):3714-6. (PMID: 20547800)
      Parasitol Res. 2007 Feb;100(3):589-92. (PMID: 17024359)
      Mol Biochem Parasitol. 2000 Apr 30;108(1):13-23. (PMID: 10802315)
      Mol Biochem Parasitol. 1997 Apr;85(2):161-9. (PMID: 9106190)
      PLoS Pathog. 2010 Mar 26;6(3):e1000830. (PMID: 20360965)
      Trop Med Int Health. 2005 Jun;10(6):521-9. (PMID: 15941414)
      Exp Parasitol. 1998 May;89(1):1-8. (PMID: 9603482)
      Acta Trop. 2012 Jan;121(1):13-8. (PMID: 22001304)
      Antimicrob Agents Chemother. 2011 Jun;55(6):2813-7. (PMID: 21422213)
      Acta Trop. 2009 Apr;110(1):75-9. (PMID: 19283899)
      Malar J. 2011 Dec 20;10:378. (PMID: 22185615)
      Am J Trop Med Hyg. 2009 Sep;81(3):525-8. (PMID: 19706926)
      Ann Trop Med Parasitol. 2004 Jan;98(1):85-8. (PMID: 15000735)
      Ann Trop Med Parasitol. 2003 Mar;97(2):119-24. (PMID: 12803866)
      J Infect Dis. 2003 Jun 1;187(11):1828-9. (PMID: 12751044)
      Antimicrob Agents Chemother. 2004 Mar;48(3):879-89. (PMID: 14982779)
      PLoS One. 2009;4(2):e4551. (PMID: 19234601)
      Int J Infect Dis. 2010 Sep;14 Suppl 3:e123-8. (PMID: 20399698)
      Lancet. 2000 Jul 22;356(9226):297-302. (PMID: 11071185)
      J Clin Invest. 2004 Apr;113(8):1084-92. (PMID: 15085184)
      Pharmacol Rev. 2005 Mar;57(1):117-45. (PMID: 15734729)
      BMJ. 2012 Jul 24;345:e4389. (PMID: 22833603)
      PLoS One. 2012;7(1):e28957. (PMID: 22303437)
      Malar J. 2007 Nov 13;6:148. (PMID: 17999755)
      Malar J. 2011 Jan 28;10:18. (PMID: 21272384)
      Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):160-9. (PMID: 18165489)
    • Grant Information:
      089275 United Kingdom WT_ Wellcome Trust; 093956 United Kingdom WT_ Wellcome Trust
    • الرقم المعرف:
      0 (Antimalarials)
      0 (Artemisinins)
      0 (DNA, Protozoan)
      0 (Drug Combinations)
      0 (Folic Acid Antagonists)
      0 (Protozoan Proteins)
      37338-39-9 (fanasil, pyrimethamine drug combination)
      60W3249T9M (Artesunate)
      88463U4SM5 (Sulfadoxine)
      Z3614QOX8W (Pyrimethamine)
    • الموضوع:
      Date Created: 20130319 Date Completed: 20130624 Latest Revision: 20211021
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC3607912
    • الرقم المعرف:
      10.1186/1475-2875-12-96
    • الرقم المعرف:
      23497229